NuVasive Announces Conference Call and Webcast of First Quarter 2009 Results
April 14 2009 - 6:28PM
PR Newswire (US)
SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
products for minimally disruptive surgical treatments for the
spine, announced today details relating to its first quarter 2009
earnings announcement, which will take place on Wednesday, April
22, 2009 after the close of the market. NuVasive will hold a
conference call on Wednesday, April 22, 2009 at 5:30 p.m. ET / 2:30
p.m. PT to discuss the results. The dial-in numbers are
1-877-407-4018 for domestic callers and 1-201-689-8471 for
international. A live webcast of the conference call will be
available online from the investor relations page of the Company's
corporate website at http://www.nuvasive.com/. After the live
webcast, the call will remain available on NuVasive's website,
http://www.nuvasive.com/, through May 22, 2009. In addition, a
telephonic replay of the call will be available until May 6, 2009.
The replay dial-in numbers are 1-877-660-6853 for domestic callers
and 1-201-612-7415 for international callers. Please use account
number 3055 and conference ID number 320044. About NuVasive
NuVasive is a medical device company focused on the design,
development, and marketing of products for the surgical treatment
of spine disorders. The Company's product portfolio is focused
primarily on the $4.6 billion U.S. spine implant market.
Additionally, the Company has expanded into the $1.5 billion global
biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum
Access Surgery, or MAS(R) platform. The MAS platform combines four
categories of products that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and
safe, easy reproducibility for the surgeon: NeuroVision(R), a
proprietary software-driven nerve avoidance system; MaXcess(R), a
unique split-blade retractor system; a wide variety of specialized
implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily
living much faster than conventional approaches. Having redefined
spine surgery with the MAS platform's lateral approach, known as
eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an
entire spine franchise. With nearly 50 products today spanning
lumbar, thoracic and cervical applications, the Company will
continue to expand and evolve its offering predicated on its
R&D focus and dedication to outstanding service levels
supported by a culture of Absolute Responsiveness(R). NuVasive
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties that could cause
actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or
clearance for NuVasive's products or devices, including risks that
such process could be significantly delayed; the possibility that
the FDA may require significant changes to NuVasive's products or
clinical studies; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk
that competitors may develop superior products or may have a
greater market position enabling more successful commercialization;
the risk that additional clinical data may call into question the
benefits of NuVasive's products to patients, hospitals and
surgeons; and other risks and uncertainties more fully described in
NuVasive's press releases and periodic filings with the Securities
and Exchange Commission. NuVasive's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances
arising after the date on which it was made. Contact: Kevin C.
O'Boyle EVP & Chief Financial Officer NuVasive, Inc.
858-909-1998 Investors: Patrick F. Williams Vice President, Finance
& Investor Relations NuVasive, Inc. 858-638-5511 Media: Jason
Rando The Ruth Group 646-536-7025 DATASOURCE: NuVasive, Inc.
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer,
+1-858-909-1998, , or Patrick F. Williams, Vice President, Finance
& Investor Relations, +1-858-638-5511, , both of NuVasive,
Inc.; or Jason Rando of The Ruth Group, +1-646-536-7025, Web Site:
http://www.nuvasive.com/
Copyright